EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 688 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell... October 8, 2024 PFS Benefit in Patients with Metastatic Breast Cancer Receiving Matched Treatments... October 11, 2022 Scientists Link a Single Type of Bacteria to Colorectal Cancer April 19, 2024 Is there a right way to check your body for cancer? March 29, 2022 Load more HOT NEWS FDA Approves Nivolumab in Combination with Chemotherapy for Metastatic Gastric Cancer... GreaterGood Partners with Organization of Hope to Deliver Toys and Necessities... FDA Grants Accelerated Approval to Adagrasib for KRAS G12C-Mutated NSCLC FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma
